ºÚÁÏÍø

ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
ºÚÁÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ºÚÁÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 3330

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Recommended Journals
Share This Page

LilrB2 inhibition unlocks a new hope in Alzheimer�s disease therapy

6th World Congress on Biotechnology

Ruchi Jakhmola Mani and Deepshikha Pande Katare

Amity University, India

Posters-Accepted Abstracts: J Biotechnol Biomater

DOI:

Abstract
Alzheimerâ��s disease (AD) is a progressive and irreversible brain illness which gradually abolishes oneâ��s cognitive skills and rational thinking. The two major hallmarks of AD are the extracellular deposition of the Amyloid-beta (A�²) fragments resulting in plaques and intracellular accumulation of neurofibrillary tangles of tau protein. LilrB2 is a recently discovered receptor for A�² and is responsible for the increased accumulation and reduced clearance of A�² from the brain. Therefore, LilrB2 inhibition can suppress the aggregation of A�² plaques. In this study we have computationally modeled the 3D-structure of four isoforms of LilrB2. Structures were later super-imposed to calculate their RMSD and individually docked with A�² to examine the most appropriate isoform for inhibition. Virtual screening of best isoform reports some potential compounds which can inhibit LilrB2. Studies are underway to validate the identified compounds in the animal model of AD.
Biography

Ruchi Jakhmola Mani is a PhD scholar and Faculty of Bioinformatics at Amity Institute of Biotechnology, Amity University, India. She has completed her Master’s degree in Bioinformatics from Panjab University, Chandigarh. She has six years of teaching experience with some peer-reviewed publications. At present, she is working with zebrafish model of Alzheimer’s disease.

Email: ruchijakhmola@gmail.com

International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top